

Supplementary file 16. Other articles on cardiovascular medicines quality included in the review

Title	First author	Year
Aspirin-A National Survey I: Semiautomated Determination of Aspirin in Bulk and Tablet Formulations and Salicylic Acid in Tablet Formulations [1]	William E. Juhl	1979
Monitoring the Purity of Pharmaceutical Heparin Preparations by High-Field 1H-Nuclear Magnetic Resonance Spectroscopy [2]	Neville, George A	1988
Drug Quality Control Work in DARU: Observations during 1983-1986 [3]	Kibwage, I.O.	1992
Quality Control of Pharmaceuticals In The Caribbean [4]	Dennis.P	1992
Drug Quality Control Work in Drug Analysis and Research Unit: Observation During 1991-1995 [5]	Kibwage, I.O.	1999
Drug Quality Control in Kenya: Observation in Drug Analysis and Research Unit during the Period 1996-2000 [6]	Thoithi, G.N.	2002
Magic Bullet Gone Astray: provides guidance to organizations for implementing effective anti-counterfeiting policies Medications and the Internet [7]	Michael A.Veronin	2004
Mongolia Pharmaceutical Sector Assessment Report [8]	Salik Govind	2004
Substandard life-saving drugs: a global concern [9]	Andreotti, F	2005
UV spectrophotometric determination of clopidogrel and repaglinide [10]	Sankar, D. G.	2005
Étude de la qualité des médicaments génériques DCI achetés par la Pharmacie Populaire du Mali dans le cadre des appels d'offres de 2002 à 2005 [11]	Issiaka C	2006
Monitoring of simvastatin impurities by HPLC with microemulsion eluents [12]	Malenovic,A	2006
Amlodipine besilate screening in pharmaceutical preparations by CE [13]	P Jankovics	2008
Contaminated heparin preparations, severe adverse events and the contact system [14]	Ramacciotti, E	2008
Contaminated heparin products recalled [15]	WHO Drug information	2008
Drug Quality Control in Kenya: Observation in the Drug Analysis and Research Unit During the Period 2001-2005 [16]	Thoithi.G.N	2008
Heparin quality control in the Brazilian market: implications in the cardiovascular surgery [17]	MELO, E	2008
Les heparines contaminees [18]	Monneret, C	2008
UK Government action on counterfeit medicines [19]	The pharmaceutical journal	2008
Analysis of pharmaceutical heparins and potential contaminants using 1H-NMR and PAGE [20]	Zhang, Z	2009
Comparative stability of repackaged metoprolol tartrate tablets [21]	Y Yang	2009
Counterfeit Drugs: Coming to a Pharmacy Near You with an Update for 2009 [22]	Yankus. W	2009
Identifying Counterfeit Medicines Using near Infrared Spectroscopy [23]	Moffat, AC	2009
Quality of medicines stored together in multi-compartment compliance aids [24]	P. Donyai	2009
Raids uncover counterfeit drugs [25]	Sagita, Dessy	2009
Comparison of established and novel purity tests for the quality control of heparin by means of a set of 177 heparin samples [26]	Alban,S	2010
Composition of OSCS-contaminated heparin occurring in 2008 in batches on the German market [27]	T. Beyer	2010
Los medicamentos falsificados en Peru [28]	Moreno Exebio,LE	2010
Post Marketing Surveillance on Propranolol and Atenolol Tablets Manufactured in Iran [29]	Khabnadideh,S	2010

Title	First author	Year
Tablet splitting: Product quality assessment of metoprolol succinate extended release tablets [30]	Na Zhao	2010
Contaminants in heparin: Review of the literature, molecular profiling, and clinical implications [31]	Eduardo Ramacciotti	2011
In vitro-in vivo correlation of four commercial brands of aspirin tablets marketed in Nigeria [32]	Bamigbola E. A	2011
Simple fluorescence assay for quantification of OSCS in heparin. [33]	Luhn, S	2011
Unveiling the Mystery of Online Pharmacies: an Audit Study [34]	Bate, R.	2012
Atorvastatin Generics Obtained from Multiple Sources Worldwide Contain a Methylated Impurity that Reduces Their HMG-CoA Reductase Inhibitory Effects [35]	Richard Preston Mason	2013
Characterization of currently marketed heparin products: Key tests for LMWH quality assurance [36]	Hongping Ye	2013
In vitro studies of amlodipine besylate tablet and comparison with foreign brand leader in Nepal [37]	Tekendra Pant	2013
Liquid dosage forms extemporaneously prepared from commercially available products - considering new evidence on stability [38]	Haywood, A.	2013
Quality Performance of Drugs Analyzed in the Drug Analysis and Research Unit (DARU) during the Period 2006-2010 [39]	Abuga K.O.	2013
RP-LC simultaneous quantitation of co-administered drugs for (non-insulin dependent) diabetic mellitus induced dyslipidemia in active pharmaceutical ingredient, pharmaceutical formulations and human serum with UV-detector [40]	Arayne, M	2013
Substandard drugs: A potential crisis for public health [41]	Johnston,A	2013
A systematic review of counterfeit and substandard medicines in field quality surveys [42]	Abdulaziz, A.F.	2014
Chromatographic determination of clopidogrel bisulfate; detection and quantification of counterfeit Plavix tablets [43]	Mona E. ElTantawy	2014
Degradation study of different brands of amlodipine using UV spectrophotometer [44]	Naveed, S	2014
Development and validation of HPLC dissolution assay of simvastatin tablets under normal and accelerated conditions [45]	EL Karbanea,M	2014
Evaluation of the Pharmaceutical Characteristics of Various Enteric-Coated Aspirin Tablets under Different Storage Conditions [46]	Abe,T	2014
Liquid chromatography with tandem mass spectrometry for the simultaneous identification and quantification of cardiovascular drugs applied to the detection of substandard and falsified drugs [47]	M Bernard	2014
Quality and Availability of Medicines in Public Health Facilities of Kerala, Indian State an Analysis [48]	Lekshmi. S	2014
Recent Applications of Analytical techniques for counterfeit drug analysis: A Review [49]	Kumar, R.	2014
Drug Quality: Postmarket Sampling and Testing Results for Drugs (FY 2015) [50]	US FDA	2015
Surveillance of Quality of Medicines Available in the Nepalese Market: A Study from Kathmandu Valley [51]	Gyanwali, P.	2015
In vitro and in vivo postmarketing surveillance of valsartan, alone or in combination with amlodipine or hydrochlorothiazide, among Palestinian hypertensive patients [52]	Zaid,N.A	2016
National Drug Survey - The Core Expert Committee [53]	Surinder Singh	2016
Process validation of tablet containing Irbesartan 300mg and Hydrochlorothiazide 12.5mg [54]	Z Hussain	2016
Drug Quality: Postmarket Sampling and Testing Results for Drugs (FY 2016) [55]	US FDA	2017
Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.[56]	Trippe, Z. A.	2017
Investigations Of The Quality Medicines Distributed In Myanmar And Cambodia, Through Different Surveys [57]	Islam, R.	2017

Title	First author	Year
Poor-Quality and Counterfeit Drugs: A Systematic Assessment of Prevalence and Risks Based on Data Published From 2007 to 2016. [58]	Koczwara, A.	2017
A Study on Spurious and Not of Standard Quality Drugs in the State of Andhra Pradesh [59]	Praveen Kumar G	2018
After Valsartan Recalls, Regulators Grapple with Nitrosamine Contamination in APIs [60]	Shanley A	2018
Comparison of uv spectrophotometry and hplc methods for the determination of pharmaceutical equivalence of clopidogrel tablet brands marketed in Nigeria [61]	S. E. Ukwueze	2018
Development and validation of a hydrophilic interaction liquid chromatography method for the quantitation of impurities in fixed-dose combination tablets containing rosuvastatin and metformin [62]	Machairas. G	2018
Inorganic analysis of falsified medical products using X-ray fluorescence spectroscopy and chemometrics [63]	Herve.R	2018
NDMA impurity in valsartan and other pharmaceutical products: Analytical methods for the determination of N-nitrosamines [64]	Parr.K.M	2018
Regulatory response to contaminated valsartan [65]	Rita Banzi	2018
WHO pharmaceuticals Newsletter No.5 2018 [66]	WHO	2018
Analysis of an impurity, N-nitrosodimethylamine, in valsartan drug substances and associated products using GC-MS [67]	Tsutsumi.T	2019
Current status of angiotensin receptor blocker recalls[68]	P Moon Gunasekaran	2019
Development of quantitative HPTLC-densitometry methods following a model process for transfer of TLC screening methods for pharmaceutical products containing moxifloxacin HCl, ofloxacin, amoxicillin trihydrate, acetylsalicylic acid + acetaminophen + caffeine, nimesulide, irbesartan, and pantoprazole [69]	Zeng, B	2019
Falsified and substandard cardiovascular drugs in Africa: a need for continued monitoring strategies [70]	Marie Antignac	2019
Low quality of some generic cardiovascular medicinal products represents a matter for growing concern [71]	Juan Tamargo	2019
Public Perception toward E-commerce of Medicines and Comparative Pharmaceutical Quality Assessment Study of Two Different Products of Furosemide Tablets from Community and Illicit Online Pharmacies [72]	Ashames, A	2019
Short commentary on NDMA (N-nitrosodimethylamine) contamination of valsartan products [73]	David J. Snodin	2019
Defibrotide falsifie et contamine identifie dans les regions de l'OMS de l'Europe, Mediterranee orientale et du Pacifique occidental [74]	-1	2020
Substandard, falsified and unregistered medicines in Latin America, 2017-2018 [75]	Rojas-Cortes, R.	2020
Stability of essential drugs in the field: Results of a study conducted over a two-year period in Burkina Faso [76]	Ballereau.F	1997

- Juhl WE, Kirchoefer RD. Aspirin—a national survey I: Semiautomated determination of aspirin in bulk and tablet formulations and salicylic acid in tablet formulations. *J Pharm Sci* 1980;**69**:544–8. doi:10.1002/jps.2600690517
- Neville GA, Mori F, Holme KR, *et al.* Monitoring the purity of pharmaceutical heparin preparations by high-field 1H-nuclear magnetic resonance spectroscopy. *J Pharm Sci* 1988;**78**:101–4. doi:http://dx.doi.org/10.1002/jps.2600780205
- Kibwage IO, Ogeto JO, Maitai CK, *et al.* Drug quality control work in Daru: observations during 1983-1986. *East Afr Med J* 1992;**69**:577–80. http://www.ncbi.nlm.nih.gov/pubmed/1473513 (accessed 25 Sep 2019).
- Dennis P, Edgrilll L., Allen M. Quality control of pharmaceuticals in the Caribbean. *Int. Pharm. J.* http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&NEWS=N&AN=22151866 (accessed 25 Sep 2019).

- 5 Kibwage I, JT K, Gathu L, *et al.* Drug Quality Control Work in Drug Analysis and Research Unit: Observation During 1991-1995. Published Online First: 1999.<http://erepository.uonbi.ac.ke/handle/11295/10357?show=full> (accessed 25 Sep 2019).
- 6 Thoithi G, Abuga K, Nguyo J, *et al.* Drug Quality Control in Kenya: Observation in Drug Analysis and Research Unit during the Period 1996-2000. *East Cent African J Pharm Sci* 2004;**5**:28–32. doi:10.4314/ecajps.v5i2.9684
- 7 Veronin MA, Youan B-BC. Magic bullet gone astray: medications and the Internet. *Science (80-)* 2004;**305**:481–2.<https://go.gale.com/ps/anonymou?id=GALE%7CA120350491&sid=googleScholar&v=2.1&it=r&linkaccess=fulltext&issn=00368075&p=AONE&sw=w> (accessed 25 Sep 2019).
- 8 Govind S. Mongolia Pharmaceutical Sector Assessment Report. Published Online First: 2004.<http://apps.who.int/medicinedocs/documents/s18614en/s18614en.pdf> (accessed 25 Sep 2019).
- 9 Andreotti F, Crea F. Substandard life-saving drugs: a global concern. *Eur Heart J* 2005;**26**:858–60. doi:10.1093/eurheartj/ehi219
- 10 Gowri Sankar D, Kalyan Sumanth S, Pawar AK., *et al.* UV spectrophotometric determination of clopidogrel and repaglinide. *Asia J Chem* 2005;**17**.http://www.asianjournalofchemistry.co.in/User/ViewFreeArticle.aspx?ArticleID=17_3_99 (accessed 25 Sep 2019).
- 11 Issiaka CAMARA. Étude de la qualité des médicaments génériques DCI achetés par la Pharmacie Populaire du Mali dans le cadre des appels d'offres de 2002 à 2005.
- 12 Malenovic A, Medenica M, Ivanovic D. Monitoring of simvastatin impurities by HPLC with microemulsion eluents. *Chromatographia* 2006;**63**:S95–100. doi:<http://dx.doi.org/10.1365/s10337-006-0747-4>
- 13 Jankovics P, Németh T, Németh-Palotás J, *et al.* Amlodipine besilate screening in pharmaceutical preparations by CE. *Chromatographia* 2008;**68**:S43–8. doi:<http://dx.doi.org/10.1365/s10337-008-0620-8>
- 14 Ramacciotti E, Wahi R, Messmore HL, *et al.* Contaminated heparin preparations, severe adverse events and the contact system. *Clin Appl Thromb* 2008;**14**:489–91. doi:<http://dx.doi.org/10.1177/1076029608324291>
- 15 WHO. Contaminated heparin products recalled. *WHO Drug Inf* 2008;**22**:10.http://www.who.int/medicines/publications/druginformation/issues/22_1_2008.pdf
- 16 Thoithi G., Abuga K., Nguyo J. Drug Quality Control in Kenya: Observation in the Drug Analysis and Research Unit During the Period 2001-2005. *East Cent. African J. Pharm. Sci.* 2008;**74**–81.https://www.researchgate.net/publication/272459027_Drug_Quality_Control_in_Kenya_Observation_in_the_Drug_Analysis_and_Research_Unit_During_the_Period_2001-2005 (accessed 25 Sep 2019).
- 17 Melo E, Pereira M, Cunha R, *et al.* Heparin quality control in the Brazilian market: Implications in the cardiovascular surgery. *Brazilian J Cardiovasc Surg* 2008;**23**:169–74.http://www.scielo.br/pdf/rbccv/v23n2/en_v23n2a04.pdf
- 18 Monneret C. Les héparines contaminées. *Ann Pharm Fr* 2008;**66**:212–5. doi:<http://dx.doi.org/10.1016/j.pharma.2008.07.004>
- 19 UK Government action on counterfeit medicines. *Pharm. J.* <https://www.pharmaceutical-journal.com/opinion/comment/uk-government-action-on-counterfeit-medicines/10008049.article?firstPass=false> (accessed 25 Sep 2019).
- 20 Zhang Z, Li B, Suwan J, *et al.* Analysis of pharmaceutical heparins and potential contaminants using ¹H-NMR and PAGE. *J Pharm Sci* 2009;**98**:4017–26. doi:<http://dx.doi.org/10.1002/jps.21729>
- 21 Yang Y, Gupta A, Carlin A, *et al.* Comparative stability of repackaged metoprolol tartrate tablets. *Elsevier* doi:<https://doi.org/10.1016/j.ijpharm.2009.10.040>

- 22 Yankus W. Counterfeit Drugs: Coming to a Pharmacy Near You with an Update for 2009. *Am. Counc. Sci. Heal.* 2009. https://drive.google.com/file/d/1Y-6zRTH6GHabWIMnV15JbpTMMum61b_d/view (accessed 3 Jun 2019).
- 23 Moffat AC, Assi S, Watt RA. Identifying Counterfeit Medicines Using near Infrared Spectroscopy. *J Near Infrared Spectrosc* 2010;**18**:1–15. doi:10.1255/jnirs.856
- 24 Quality of medicines stored together in multi-compartment compliance aids. *J Clin Pharm Ther* 2010;**35**:533–43. doi:<http://dx.doi.org/10.1111/j.1365-2710.2009.01129.x>
- 25 Sagita D. Raids uncover counterfeit drugs. 2009. <https://drive.google.com/file/d/14plcZWR6p6NYjMbIIszhONmmAT8oHFYV/view> (accessed 16 Dec 2020).
- 26 Alban S, Lühn S, Schiemann S, *et al.* Comparison of established and novel purity tests for the quality control of heparin by means of a set of 177 heparin samples. *Springer* doi:10.1007/s00216-010-4169-7
- 27 Beyer T, Matz M, Brinz D, *et al.* Composition of OSCS-contaminated heparin occurring in 2008 in batches on the German market. *Eur J Pharm Sci* 2010;**40**:297–304. doi:10.1016/j.ejps.2010.04.002
- 28 Exebio LEM, Rodríguez J, Sayritupac F. Los medicamentos falsificados en Perú. *Rev Panam Salud Pública* 2010;**27**:138–43. doi:10.1590/S1020-49892010000200008
- 29 Iranian Association of Pharmaceutical Scientists. S, Mohammadi Samani S, Yarmohammadi G, *et al.* *Post Marketing Surveillance on Propranolol and Atenolol Tablets Manufactured in Iran.* Iranian Association of Pharmaceutical Scientists 2010. http://www.ijps.ir/article_2110.html (accessed 12 Jun 2019).
- 30 Zhao N, Zidan A, Tawakkul M, *et al.* Tablet splitting: Product quality assessment of metoprolol succinate extended release tablets. *Int J Pharm* 2010;**401**:25–31. doi:<http://dx.doi.org/10.1016/j.ijpharm.2010.09.004>
- 31 Ramacciotti E, Clark M, Sadeghi N, *et al.* Contaminants in heparin: Review of the literature, molecular profiling, and clinical implications. *Clin Appl Thromb* 2011;**17**:126–35. doi:<http://dx.doi.org/10.1177/1076029610392214>
- 32 Bamigbola E A, Ibrahim M A, Attama A A, *et al.* In vitro-in vivo correlation of four commercial brands of aspirin tablets marketed in Nigeria. *African J Pharm Pharmacol* 2011;**5**:1648–54. doi:10.5897/AJPP10.179
- 33 Luhn S, Schiemann S, Alban S, *et al.* Simple fluorescence assay for quantification of OSCS in heparin. *Anal Bioanal Chem* 2011;**399**:673–80. doi:10.1007/s00216-010-3867-5
- 34 Bate R, Jin GZ, Mathur A. Unveiling the Mystery of Online Pharmacies: an Audit Study. 2012. https://www.researchgate.net/publication/254072335_Unveiling_the_Mystery_of_Online_Pharmacies_an_Audit_Study (accessed 25 Sep 2019).
- 35 Mason RP, Jacob R. Atorvastatin generics obtained from multiple sources worldwide contain a methylated impurity that reduces their hmg-coa reductase inhibitory effects. *J Clin Lipidol* 2013;**7**:287. doi:<http://dx.doi.org/10.1016/j.jacl.2013.03.096>
- 36 Ye H, Toby TK, Sommers CD, *et al.* Characterization of currently marketed heparin products: Key tests for LMWH quality assurance. *J Pharm Biomed Anal* 2013;**85**:99–107. doi:<http://dx.doi.org/10.1016/j.jpba.2013.06.033>
- 37 Pant T, Subedi KMRK. In vitro studies of amlodipine besylate tablet and comparison with foreign brand leader in Nepal. 2013. <https://ijpsr.com/bft-article/in-vitro-studies-of-amlodipine-besylate-tablet-and-comparison-with-foreign-brand-leader-in-nepal/> (accessed 16 Dec 2020).
- 38 Haywood A, Glass BD. Liquid dosage forms extemporaneously prepared from commercially available products - Considering new evidence on stability. *J Pharm Pharm Sci* 2013;**16**:441–55. <http://ejournals.library.ualberta.ca/index.php/JPPS/article/view/19411/15507>
- 39 Abuga KO, Amugune BK, Ndwigah SN, *et al.* Quality Performance of Drugs Analyzed in the Drug Analysis and Research Unit (DARU) during the Period 2006-

2010. *East Cent African J Pharm Sci* 2013;**16**.https://profiles.uonbi.ac.ke/okibwage/files/full_paper.pdf (accessed 25 Sep 2019).
- 40 Arayne MS, Sultana N, Tabassum A. RP-LC simultaneous quantitation of co-administered drugs for (non-insulin dependent) diabetic mellitus induced dyslipidemia in active pharmaceutical ingredient, pharmaceutical formulations and human serum with UV-detector. *Clin Chim Acta* 2013;**425**:54–61. doi:10.1016/j.cca.2013.06.020
- 41 Johnston A, Holt DW. Substandard drugs: a potential crisis for public health. *Br J Clin Pharmacol* 2014;**78**:218–43. doi:10.1111/bcp.12298
- 42 Alghannam A, Evans S, Schifano F, *et al.* A systematic review of counterfeit and substandard medicines in field quality surveys. *Integr Pharm Res Pract* 2014;**3**:71. doi:10.2147/IPRP.S63690
- 43 ETantawy M., Bebawy L. Chromatographic determination of clopidogrel bisulfate; detection and quantification of counterfeit Plavix tablets. *Bull Fac Pharmacy, Cairo Univ* 2014;**52**:91–101. doi:<http://dx.doi.org/10.1016/j.bfopcu.2014.04.003>
- 44 Naveed S, Jawaid W. Degradation study of different brands of amlodipine using UV spectrophotometer. *J Sci Innov Res*http://www.jsirjournal.com/Vol3_Issue4_04.pdf (accessed 26 Mar 2019).
- 45 El Karbane M, Ramli Y, Amood Al-Kamarany M, *et al.* Development and validation of HPLC dissolution assay of simvastatin tablets under normal and accelerated conditions. *J Chem Pharm Res* 2014;**6**:886–93.<http://jocpr.com/vol6-iss6-2014/JCPR-2014-6-6-886-893.pdf>
- 46 Abe T, Yanagihara Y, Uchino T, *et al.* Evaluation of the Pharmaceutical Characteristics of Various Enteric-Coated Aspirin Tablets under Different Storage Conditions. *Chem Pharm Bull* 2014;**62**:617–26. doi:10.1248/cpb.c13-00580
- 47 Bernard M, Akrouf W, Van Buu CT, *et al.* Liquid chromatography with tandem mass spectrometry for the simultaneous identification and quantification of cardiovascular drugs applied to the detection of substandard and falsified drugs. *J Sep Sci* 2015;**38**:562–70. doi:10.1002/jssc.201401301
- 48 Lekshmi S, Mohanta G., Farooq A, *et al.* Quality and Availability of Medicines in Public Health Facilities of Kerala, Indian State an Analysis. *Int J Adv Sci Eng Technol* 2014;**2**.http://www.iraj.in/journal/journal_file/journal_pdf/6-87-142044869595-97.pdf (accessed 25 Sep 2019).
- 49 Kumar R. Recent applications of analytical techniques for counterfeit drug analysis: A review. *Int J PharmTech Res* 2014;**6**:646–65.[http://sphinxssai.com/2014/PTVOL6/PT=31\(646-665\)AJ14.pdf](http://sphinxssai.com/2014/PTVOL6/PT=31(646-665)AJ14.pdf)
- 50 Drug Quality: Postmarket Sampling and Testing Results for Drugs (FY 2015) | FDA. US FDA. 2015.<https://www.fda.gov/media/103649/download> (accessed 25 Sep 2019).
- 51 Gyanwali P, Humagain BR, Aryal KK, *et al.* Surveillance of Quality of Medicines Available in the Nepalese Market: A Study from Kathmandu Valley. *J Nepal Health Res Counc* 2015;**13**:233–40.<http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed16&NEWS=N&AN=616144386>
- 52 Zaid AN, Ghanem M, Shweiki D, *et al.* In vitro and in vivo postmarketing surveillance of valsartan, alone or in combination with amlodipine or hydrochlorothiazide, among palestinian hypertensive patients. *Ther Clin Risk Manag* 2016;**12**:1425–32. doi:<http://dx.doi.org/10.2147/TCRM.S110727>
- 53 Surinder Singh. National Drug Survey - The Core Expert Committee. Natl. Inst. Biol. 2016.http://nib.gov.in/Drug_Survey.html (accessed 25 Sep 2019).
- 54 Hussain Z, Baqir S, Naqvi S, *et al.* Process validation of tablet containing Irbesartan 300mg and Hydrochlorothiazide 12.5mg. *Int J Sci Eng Res* 2016.
- 55 Drug Quality: Postmarket Sampling and Testing Results for Drugs (FY 2016) | FDA. US FDA. 2016.<https://www.fda.gov/media/103635/download> (accessed 25 Sep 2019).
- 56 Trippe ZA, Brendani B, Meier C. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports. *Drug Saf* 2017;**40**:293–303. doi:<http://dx.doi.org/10.1007/s40264-016-0499-5>

- 57 Islam R. Investigations Of The Quality Medicines Distributed In Myanmar And Cambodia, Through Different Surveys. Grad. Sch. Med. Sci. Technol. Kanazawa Univ. https://kanazawa-u.repo.nii.ac.jp/?action=repository_action_common_download&item_id=43361&item_no=1&attribute_id=31&file_no=1 (accessed 9 Dec 2019).
- 58 Koczwara A, Dressman J. Poor-Quality and Counterfeit Drugs: A Systematic Assessment of Prevalence and Risks Based on Data Published From 2007 to 2016. *J Pharm Sci* 2017;**106**:2921–9. doi:10.1016/j.xphs.2017.05.018
- 59 Praveen Kumar G, Ravi Shankar A. A Study on Spurious and Not of Standard Quality Drugs in the State of Andhra Pradesh. *African J Pharm Pharmacol* Published Online First: 2018.<https://academicjournals.org/journal/AJPP/article-full-text-pdf/4EC3AD856268> (accessed 25 Sep 2019).
- 60 Shanley A. After Valsartan Recalls, Regulators Grapple with Nitrosamine Contamination in APIs. Published Online First: 2018.<http://www.pharmtech.com/after-valsartan-recalls-regulators-grapple-nitrosamine-contamination-apis> (accessed 27 Mar 2019).
- 61 Ukwueze SE, Uliah C. Comparison of UV spectrophotometry and HPLC methods for the determination of pharmaceutical equivalence of clopidogrel tablet brands marketed in Nigeria. *Eur J Pharm Med Res* 2018;**5**:126–30.<http://www.ejpmr.com/admin/download/article/MTUyNTA2Nzk2MC5wZGY=>
- 62 Machairas G, Panderi I, Geballa-Koukoula A, *et al.* Development and validation of a hydrophilic interaction liquid chromatography method for the quantitation of impurities in fixed-dose combination tablets containing rosuvastatin and metformin. *Talanta* 2018;**183**:131–41. doi:10.1016/j.talanta.2018.02.068
- 63 Rebiere H, Kermaidic A, Ghyselinck C, *et al.* Inorganic analysis of falsified medical products using X-ray fluorescence spectroscopy and chemometrics. *Talanta* 2019;**195**:490–6. doi:<http://dx.doi.org/10.1016/j.talanta.2018.11.051>
- 64 Parr M, Joseph J. NDMA impurity in valsartan and other pharmaceutical products: Analytical methods for the determination of N-nitrosamines. *J Pharm Biomed Anal* 2019;**164**:536–49. doi:<http://dx.doi.org/10.1016/j.jpba.2018.11.010>
- 65 Banzi R. Regulatory response to contaminated valsartan. *BMJ* 2018;**362**:k3855. doi:<http://dx.doi.org/10.1136/bmj.k3855>
- 66 WHO pharmaceuticals Newsletter No.5 2018. WHO Published Online First: 2018.<https://apps.who.int/iris/bitstream/handle/10665/275697/WPN-2018-05-eng.pdf?sequence=1&isAllowed=y> (accessed 25 Sep 2019).
- 67 Tsutsumi T, Akiyama H. Analysis of an impurity, N-nitrosodimethylamine, in valsartan drug substances and associated products using GC-MS. *Biol Pharm Bull* Published Online First: 2019.https://www.jstage.jst.go.jp/article/bpb/advpub/0/advpub_b19-00006/_article-char/ja/ (accessed 27 Mar 2019).
- 68 Gunasekaran PM, Chertow GM, Bhalla V, *et al.* Current status of angiotensin receptor blocker recalls. *Hypertension* 2019;**74**:1275–8. doi:<http://dx.doi.org/10.1161/HYPERTENSIONAHA.119.13955>
- 69 Zeng BS, Gu YR, Nguyen K, *et al.* Development of quantitative HPTLC-densitometry methods following a model process for transfer of TLC screening methods for pharmaceutical products containing moxifloxacin HCl, ofloxacin, amoxicillin trihydrate, acetylsalicylic acid + acetaminophen + caffeine. *J Liq Chromatogr Relat Technol* 2019;**42**:324–9. doi:10.1080/10826076.2019.1585609
- 70 Antignac M, Bara Diop I, Macquart de Terline D, *et al.* Falsified and substandard cardiovascular drugs in Africa: a need for continued monitoring strategies. *J. Glob. Health.* 2019;**9**:010302. doi:10.7189/jogh.09.020302
- 71 Tamargo J, Journal-Cardiovascular GR-EH, undefined 2020. Low quality of some generic cardiovascular medicinal products represents a matter for growing concern. *academic.oup.com*<https://academic.oup.com/ehjcvp/article-abstract/6/3/176/5566494>
- 72 Ashames A, Bhandare R, AlAbdin SZ, *et al.* Public perception toward e-commerce of medicines and comparative pharmaceutical quality assessment study of two different products of furosemide tablets from community and illicit online pharmacies. *J Pharm Bioallied Sci* 2019;**11**:284–91. doi:10.4103/jpbs.JPBS_66_19

- 73 Snodin D., Elder DP. Short commentary on NDMA (N-nitrosodimethylamine) contamination of valsartan products. *Regul Toxicol Pharmacol* 2019;**103**:325–9. doi:<http://dx.doi.org/10.1016/j.yrtph.2019.01.007>
- 74 Defibrotide falsifie et contamine identifie dans les regions de l’OMS de l’Europe, Mediterranee orientale et du Pacifique occidental. <https://www.who.int/fr/news/item/07-05-2020-medical-product-alert-n-5-2020> (accessed 16 Dec 2020).
- 75 Rojas-Cortés R. Substandard, falsified and unregistered medicines in Latin America, 2017-2018. *Rev Panam Salud Publica/Pan Am J Public Heal* 2020;**44**. doi:10.26633/RPSP.2020.125
- 76 Ballereau F, Prazuck T, Schrive I, *et al*. Stability of essential drugs in the field: Results of a study conducted over a two-year period in Burkina Faso. *Am J Trop Med Hyg* 1997;**57**:31–6. doi:10.4269/ajtmh.1997.57.31